Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1069530 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.96Day +10.40%Mkt cap $46MOff 52W high −57.6%Vol (1Y) 59.0%
Daily closing price, split-adjusted to the current basis; 0.3y shown of 88 bars on file. Sampled to 88 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.9% of sh out |
| Days to cover14.8d |
| 13F net flow (QoQ)+0.75% |
| Top-10 13F concentration73.5% |
| Next report (est.)2026-10-27 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$77.9M |
| ROE−82.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
No return windows available for FLNA.
| Ann. volatility (1Y)59.0% |
| Ann. volatility (3Y)59.0% |
| Sharpe (1Y)−3.51 |
| Sharpe (3Y)−3.51 |
| Max drawdown (1Y)−58.4% |
| Max drawdown (3Y)−58.4% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MARSHALL WACE, LLP | 2.0M | $3M | 4.17% | −4.9% |
| TWO SIGMA INVESTMENTS, LP | 2.0M | $3M | 4.12% | +209.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $3M | 4.00% | new |
| BlackRock, Inc. | 1.4M | $2M | 2.93% | −0.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 596,242 | $1M | 1.23% | +9.2% |
| D. E. Shaw & Co., Inc. | 559,205 | $945,056 | 1.16% | +19.2% |
| GMT Capital Corp | 450,100 | $760,669 | 0.93% | new |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 447,278 | $755,900 | 0.93% | −15.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2025-09-30 | 2025-11-12 | −$0.22 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.92 | −807.7% | — | — |
| 2025-03-31 | 2025-05-08 | −$0.48 | — | — | — |
| 2024-09-30 | 2024-11-07 | −$0.58 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-27 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
